WBCIL's Breakthrough at CPHI China 2024

West Bengal Chemical Industries Limited (WBCIL) made a successful debut at CPHI China 2024, overcoming pricing challenges posed by Chinese manufacturers. The company attracted significant international interest, particularly for its injectable irons and Iron Sucrose API. This marks a critical turning point for WBCIL's global expansion plans.

In a significant breakthrough, West Bengal Chemical Industries Limited (WBCIL) has made an impressive debut at CPHI China 2024, one of the global pharmaceutical industry’s premier events. Despite competitive pricing challenges from Chinese manufacturers, WBCIL's strategic participation facilitated substantial business opportunities and forged valuable connections.

China’s market, known for its competitive pricing, has historically been difficult for Indian companies like WBCIL. However, WBCIL's bold move to engage with the international clientele at the exhibition, instead of just targeting the Chinese market, proved successful. The company attracted numerous clients from neighboring countries, significantly boosting its exhibition success.

The exhibition exceeded expectations, with notable interest from Chinese companies in WBCIL's injectable irons and the newly developed oral iron API, Iron Sucrose. This has paved the way for WBCIL to potentially enter the Chinese market. WBCIL’s remarkable performance has encouraged the company to expand its participation in future exhibitions, reflecting its growing confidence in global market expansion.

About WBCIL: Founded in 1962 in Kolkata, India, WBCIL is a leader in the pharmaceutical industry, known for its high-quality APIs. The company serves over 4,000 clients in 20+ countries and holds numerous prestigious certifications. WBCIL continues to be committed to innovation and excellence in API manufacturing.